{
  "ticker": "ILA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972179",
  "id": "02972179",
  "pages": 11,
  "price_sensitive": true,
  "date": "20250724",
  "time": "0900",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250724/pdf/06m2ygc03cx32m.pdf",
  "summary": "### Material Information Summary (Quarterly Activities Report + Appendix 4C):  \n\n#### **Key Clinical & Pipeline Developments**  \n- **ISLA-101 Phase 2a/b Trial Results**:  \n  - **Preventative cohort**: Clinically meaningful reduction in dengue viremia (viral load) and symptoms (~33% symptom incidence vs. ~63% placebo).  \n  - **Treatment cohort**: Clear drug signal observed; further data review pending.  \n- **Galidesivir Acquisition**:  \n  - Broad-spectrum antiviral acquired from BioCryst Pharmaceuticals (NASDAQ: BCRX).  \n  - Targets Marburg, Ebola, Zika; leverages FDA\u2019s **Animal Rule** for potential fast-track approval.  \n  - Priority Review Voucher (PRV) potential (recent PRVs valued >US$150m).  \n\n#### **Financial & Capital Updates**  \n- **Capital Raise**: $3.6m (AUD) via placement at $0.15/share.  \n- **Cash Balance**: $7.25m (30 June 2025), with additional $780k from options exercise post-quarter.  \n- **Cash Burn**: Net operating cash outflow of $823k (quarter), $2.77m (12-month).  \n\n#### **Near-Term Catalysts**  \n- Further ISLA-101 data review and development pathway decision.  \n- Galidesivir\u2019s **Marburg animal study** within 12 months.  \n\n**Omitted**: Director appointments, investor meetings, and operational boilerplate.",
  "usage": {
    "prompt_tokens": 6374,
    "completion_tokens": 315,
    "total_tokens": 6689,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-23T23:16:48.606070"
}